65,437 trials
Dentin Sensitivity
Primary: Change From Baseline in Schiff Sensitivity Score on Day 3 — 2.44; 2.49; 1.01; 2.37 Score on a scale — p=<.0001
Tetanus · Acellular Pertussis · Diphtheria
Primary: Number of Seroprotected Subjects Against Diphtheria (Anti-D) and Tetanus (Anti-T) — 204; 211; 204; 211 Subjects
Ciliary Body and Choroid Melanoma, Medium/Large Size · Ciliary Body and Choroid Melanoma, Small Size · Iris Melanoma
Primary: Number of Patients With Disease-free Survival (DFS) — 8 Participants
Multiple Sclerosis, Relapsing Forms
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 6; 5; 3; 3 Participants
Depressive Disorder, Major
Primary: Time to First Relapse During the Double-Blind Treatment Period (DBTP) — NA; NA days — p=0.0212
Kidney Failure, Chronic · Renal Insufficiency, Chronic
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2409021 — 2460; 2320; 2190; 2080 Nanogram per milliliter (ng/mL)
Dental Plaque
Primary: Change From Baseline (Pre-brushing) After a Single Brushing Treatment (Post-brushing) Turesky Modification of Quigley Hein Plaque Index (TPI), Positive Control Versus…
Ulcerative Colitis
Primary: Percentage of Participants Who Achieved a Clinical Remission by Total Mayo Score (TMS) at Week 12 — 12.1; 31.6; 21.8 Percentage of Participants — p=0.0142
Depression
Primary: Adherence to Antidepressant Medication — 82.0 % of days adherent
Schizophrenia
Primary: The Change in the Severity of Negative Symptoms — 48.09; 50.33; 33.91; 41.00 units on a scale
Rectal Cancer · Colon Cancer · Crohn's Disease
Primary: PINPOINT System Utility in Left Colectomy Surgery — 11; 128 Participants
Diabetes Mellitus, Type 1
Primary: Pharmacodynamics: Change From Baseline to Day 2 in 24-hour Insulin Dose — 1.85; 0.80; 7.69 insulin units — p=0.0542
Sleep Apnea, Obstructive
Primary: Participant Providing Feedback — 26 Participants
Pain, Postoperative
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 33; 47 Participants
Bioequivalence, AUC, Cmax, Pharmacokinetics
Primary: Pharmacokinetics of Memantinol by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf)) — 1920.362; 2096.669 ng*h/mL — p=0.05